NCT02128906 2026-04-16
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
3,236 trialsNCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT03618550 2026-04-16
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04237623 2026-04-16
GM-CSF With Post-Transplant Cyclophosphamide
Northside Hospital, Inc.
Phase 2 Recruiting
NCT04789681 2026-04-16
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04879121 2026-04-16
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05013892 2026-04-16
NTS-WBRT in Brain Metastases
Massachusetts General Hospital
Phase 2 Recruiting
NCT05026983 2026-04-16
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05064280 2026-04-16
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05123807 2026-04-16
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05534438 2026-04-16
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05537896 2026-04-16
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
West Virginia University
Phase 2 Recruiting
NCT05749588 2026-04-16
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Fudan University
Phase 2 Recruiting
NCT05789485 2026-04-16
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05967182 2026-04-16
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06083922 2026-04-16
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT06200155 2026-04-16
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06347705 2026-04-16
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06453486 2026-04-16
ABLATE
University Health Network, Toronto
Phase 2 Recruiting
NCT06510699 2026-04-16
PRAGMATIC
The University of Queensland
Phase 2 Recruiting
NCT06569368 2026-04-16
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06617858 2026-04-16
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06702033 2026-04-16
MINT-2
Washington University School of Medicine
Phase 2 Recruiting
NCT06782542 2026-04-16
OLUVENAZA
University of Miami
Phase 2 Recruiting
NCT06801041 2026-04-16
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06817720 2026-04-16
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06955169 2026-04-16
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
NCT07110038 2026-04-16
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07133425 2026-04-16
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT07224100 2026-04-16
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
University of Washington
Phase 2 Recruiting
NCT07283705 2026-04-16
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07294664 2026-04-16
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT07303894 2026-04-16
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07493538 2026-04-16
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT07534033 2026-04-16
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
Zhujiang Hospital
Phase 2 Recruiting
NCT03161522 2026-04-15
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03398161 2026-04-15
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT04003051 2026-04-15
Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04870762 2026-04-15
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05065801 2026-04-15
GABRINOX2
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT05336383 2026-04-15
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05355051 2026-04-15
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05529069 2026-04-15
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06066333 2026-04-15
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06218602 2026-04-15
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06458036 2026-04-15
RAISE
Children's Hospital of Philadelphia
Phase 2 Recruiting
NCT06561360 2026-04-15
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting